A UK startup has secured breakthrough device designation for a prescription-based software product using virtual reality to treat people with serious mental illness. The designation from the U.S. Food and Drug Administration should help speed adoption of the therapy, developed by Oxford VR, according to Deepak Gopalakrishna, the company’s CEO and co-founder. He credited the designation, in part, to a […]
